These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31299940)

  • 1. Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study.
    Lin AS; Chan HY; Peng YC; Chen WJ
    BMC Psychiatry; 2019 Jul; 19(1):220. PubMed ID: 31299940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders.
    Chan SKW; Chan HYV; Honer WG; Bastiampillai T; Suen YN; Yeung WS; Lam M; Lee WK; Ng RMK; Hui CLM; Chang WC; Lee EHM; Chen EYH
    Schizophr Bull; 2021 Mar; 47(2):485-494. PubMed ID: 33043960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between treatment resistance and cognitive function in schizophrenia.
    Sun J; Yee JY; See YM; Tang C; Zheng S; Ng BT; Lee J
    Singapore Med J; 2024 Oct; 65(10):552-557. PubMed ID: 39379031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients.
    Chen WJ; Liu SK; Chang CJ; Lien YJ; Chang YH; Hwu HG
    Am J Psychiatry; 1998 Sep; 155(9):1214-20. PubMed ID: 9734545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained attention deficits in nonpsychotic relatives of schizophrenic patients: a recurrence risk ratio analysis.
    Chen WJ; Chang CH; Liu SK; Hwang TJ; Hwu HG;
    Biol Psychiatry; 2004 May; 55(10):995-1000. PubMed ID: 15121483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?
    Anderson VM; McIlwain ME; Kydd RR; Russell BR
    Psychiatry Res; 2015 Dec; 230(3):811-8. PubMed ID: 26564550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists.
    Correll CU; Brevig T; Brain C
    BMC Psychiatry; 2019 Nov; 19(1):362. PubMed ID: 31727015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with cognitive dysfunction in treatment-responsive and -resistant schizophrenia: A pilot cross-sectional study.
    Suzuki Y; Watanabe K; Kanno-Nozaki K; Horikoshi S; Ichinose M; Hirata Y; Kobayashi Y; Takeuchi S; Osonoe K; Hoshino S; Miura I
    J Psychiatr Res; 2024 Oct; 178():228-235. PubMed ID: 39163661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients.
    Iasevoli F; D'Ambrosio L; Notar Francesco D; Razzino E; Buonaguro EF; Giordano S; Patterson TL; de Bartolomeis A
    Schizophr Res; 2018 Dec; 202():217-225. PubMed ID: 29934250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
    de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
    Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia.
    Ajnakina O; Horsdal HT; Lally J; MacCabe JH; Murray RM; Gasse C; Wimberley T
    Schizophr Res; 2018 Jul; 197():294-297. PubMed ID: 29472163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated intrinsic cortical curvature in treatment-resistant schizophrenia: Evidence of structural deformation in functional connectivity areas and comparison with alternate indices of structure.
    Torres-Carmona E; Ueno F; Iwata Y; Nakajima S; Song J; Mar W; Abdolizadeh A; Agarwal SM; de Luca V; Remington G; Gerretsen P; Graff-Guerrero A
    Schizophr Res; 2024 Jul; 269():103-113. PubMed ID: 38761434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol.
    Liu SK; Chen WJ; Chang CJ; Lin HN
    Neuropsychopharmacology; 2000 Mar; 22(3):311-9. PubMed ID: 10693159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study.
    Cho J; Hayes RD; Jewell A; Kadra G; Shetty H; MacCabe JH; Downs J
    Acta Psychiatr Scand; 2019 Mar; 139(3):237-247. PubMed ID: 30478891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia.
    Semiz UB; Cetin M; Basoglu C; Ebrinc S; Uzun O; Herken H; Balibey H; Algul A; Ates A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1330-6. PubMed ID: 17618026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with first-episode psychosis in northern Taiwan: neurocognitive performance and niacin response profile in comparison with schizophrenia patients of different familial loadings and relationship with clinical features.
    Yu SC; Hwang TJ; Liu CM; Chan HY; Kuo CJ; Yang TT; Wang JP; Liu CC; Hsieh MH; Lin YT; Chien YL; Kuo PH; Shih YW; Yu SL; Chen HY; Chen WJ
    BMC Psychiatry; 2024 Feb; 24(1):155. PubMed ID: 38389072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis.
    Mizuno Y; McCutcheon RA; Brugger SP; Howes OD
    Neuropsychopharmacology; 2020 Mar; 45(4):622-631. PubMed ID: 31766049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS).
    Nuechterlein KH; Green MF; Calkins ME; Greenwood TA; Gur RE; Gur RC; Lazzeroni LC; Light GA; Radant AD; Seidman LJ; Siever LJ; Silverman JM; Sprock J; Stone WS; Sugar CA; Swerdlow NR; Tsuang DW; Tsuang MT; Turetsky BI; Braff DL
    Schizophr Res; 2015 Apr; 163(1-3):38-46. PubMed ID: 25749017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the effects of treatment resistance and anticholinergic burden on cognitive function domains in patients with schizophrenia.
    Chan SKW; Pang TSW; Tsui HKH; Suen YN; Yan WC; Tsui CF; Poon LT; Chan CWH; Lo A; Cheung KM; Hui CLM; Chang WC; Lee EHM; Chen EYH; Honer WG
    Psychiatry Res; 2024 Jul; 337():115985. PubMed ID: 38820652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling cognitive impairment in treatment-resistant schizophrenia patients.
    Frydecka D; Beszłej JA; Gościmski P; Kiejna A; Misiak B
    Psychiatry Res; 2016 Jan; 235():133-8. PubMed ID: 26706131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.